Lenalidomide, Bortezomib, and Dexamethasone with Transplantation in Myeloma.

BACKGROUND: High-dose chemotherapy with autologous stem cell transplantation has been the standard treatment for young patients with newly diagnosed myeloma. However, promising emerging data with the combination of lenalidomide, bortezomib and dexamethasone (RVD) have raised questions about the role...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :N Engl J Med
Главные авторы: Attal, Michel, Lauwers-Cances, Valerie, Hulin, Cyrille, Leleu, Xavier, Caillot, Denis, Escoffre, Martine, Arnulf, Bertrand, Macro, Margaret, Belhadj, Karim, Garderet, Laurent, Roussel, Murielle, Payen, Catherine, Mathiot, Claire, Fermand, Jean Paul, Meuleman, Nathalie, Rollet, Sandrine, Maglio, Michelle E., Zeytoonjian, Andrea A., Weller, Edie A., Munshi, Nikhil, Anderson, Kenneth C., Richardson, Paul G., Facon, Thierry, Avet-Loiseau, Hervé, Harousseau, Jean-Luc, Moreau, Philippe
Формат: Artigo
Язык:Inglês
Опубликовано: 2017
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6201242/
https://ncbi.nlm.nih.gov/pubmed/28379796
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1611750
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы